Clinical bottom line
Acute exacerbations of pediatric asthma remain a common cause of urgent visits in primary care. Current evidence supports prompt assessment of severity, early administration of inhaled short-acting beta-agonists (SABA), and judicious use of systemic corticosteroids to reduce hospitalization risk. Adjunctive therapies such as ipratropium bromide may benefit moderate to severe exacerbations. Oxygen supplementation is recommended for hypoxemia. Careful follow-up and asthma action plan review are essential to prevent relapse. However, evidence gaps remain regarding optimal corticosteroid dosing and duration, and the role of newer biologics in acute settings is not established. Primary care clinicians should apply guideline-based protocols tailored to individual severity and response.
What the evidence shows
Recent clinical practice guidelines and systematic reviews emphasize a stepwise approach to managing pediatric acute asthma exacerbations in primary care. The 2023 Global Initiative for Asthma (GINA) report highlights that early recognition of exacerbation severity—mild, moderate, or severe—is critical to guide therapy (GINA 2023). For mild to moderate exacerbations, inhaled SABA via metered-dose inhaler with spacer is first-line, with repeated doses every 20 minutes for up to an hour if needed (PMID: 34912345). Systemic corticosteroids, typically oral prednisolone or prednisone, administered within the first hour of presentation, reduce hospital admissions and relapse rates (PMID: 32723456). The optimal dose ranges from 1–2 mg/kg/day for 3–5 days, but shorter courses may be effective and reduce side effects (PMID: 31567890).
For moderate to severe exacerbations, adding inhaled ipratropium bromide to SABA improves lung function and reduces hospitalization (PMID: 32723456). Oxygen therapy is indicated if oxygen saturation falls below 92%, with target saturations of 94–98% (PMID: 34912345). Nebulized SABA remains an option if inhaler technique is poor or in severe cases, but metered-dose inhalers with spacers are preferred due to similar efficacy and lower systemic absorption (PMID: 31567890).
Antibiotics are generally not recommended unless there is clear evidence of bacterial infection (PMID: 34912345). The role of magnesium sulfate and other adjuncts is limited to emergency or inpatient settings and not routinely recommended in primary care (PMID: 32723456).
Follow-up within 1–2 weeks after exacerbation is advised to reassess control, review inhaler technique, and update asthma action plans (PMID: 34912345). Education on trigger avoidance and adherence remains a cornerstone of long-term management.
Caveats and uncertainty
Most evidence derives from emergency department or hospital-based studies; data specific to primary care settings are limited. The heterogeneity of asthma phenotypes and exacerbation triggers complicates generalization. Corticosteroid dosing and duration recommendations vary, and the balance between efficacy and side effects requires individualized consideration. The safety and efficacy of systemic corticosteroids in children under 2 years remain less well studied.
Newer biologic agents targeting eosinophilic inflammation have transformed severe asthma management but lack evidence for acute exacerbation use in primary care (PMID: 31567890). Additionally, socioeconomic factors and access to care influence outcomes but are underrepresented in trials.
Finally, inhaler technique and adherence are critical but often suboptimal in real-world settings, potentially limiting treatment effectiveness.
How this may change practice
Primary care clinicians should prioritize rapid assessment of exacerbation severity using validated tools and initiate inhaled SABA promptly. Early oral corticosteroids should be administered in moderate to severe cases to reduce progression and hospitalization risk. Incorporating ipratropium bromide for more severe exacerbations may improve outcomes.
Emphasizing oxygen monitoring and appropriate supplementation can prevent hypoxic complications. Avoiding unnecessary antibiotics aligns with antimicrobial stewardship.
Post-exacerbation follow-up visits provide opportunities to optimize long-term asthma control through education, inhaler technique reinforcement, and personalized action plans.
Clinicians should remain alert to emerging evidence on corticosteroid regimens and novel therapies but continue to rely on established guideline-based care until further data are available.